Intravenous; mCRPC: Metastatic castration-resistant prostate cancer; P: Placebo ... the incidence of skeletal-related events (SREs) in bone metastatic CRPC (mCRPC). Denosumab compared with ...

Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.

Professor Adrian Crellin, 70, noticed blood in his urine and promptly sought medical attention from his GP, leading to a ...

There are currently, however, two radioligands that are United States Food and Drug Administration (FDA)-approved for the treatment of mCRPC patients: Patients with advanced prostate cancer are at ...

[25] The preferential metastatic sites in 316 patients with PC were bone (89.5% ... BM: Brain metastasis; CRPC: Castration-resistant prostate cancer; CT: Computed tomography; NA: Not assessed ...

More men are getting checked for prostate cancer and realising they have the disease at an early stage, but charity Prostate ...

Two metastatic lesions in the middle section ... that are used to diagnose prostate cancer. Source: Prostate Cancer UK A follow-up bone scan identified a tumour in the man's right shinbone ...

Since the initial diagnosis, Prof Crellin has undergone chemotherapy and radiotherapy and continues to receive hormone ...

PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...